These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 28640871)

  • 1. Nomogram to predict rectal toxicity following prostate cancer radiotherapy.
    Delobel JB; Gnep K; Ospina JD; Beckendorf V; Chira C; Zhu J; Bossi A; Messai T; Acosta O; Castelli J; de Crevoisier R
    PLoS One; 2017; 12(6):e0179845. PubMed ID: 28640871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced late urinary toxicity with high-dose intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer.
    Zapatero A; Roch M; Büchser D; Castro P; Fernández-Banda L; Pozo G; Liñán O; Martin de Vidales C; Cruz-Conde A; García-Vicente F
    Clin Transl Oncol; 2017 Sep; 19(9):1161-1167. PubMed ID: 28374321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer.
    Zelefsky MJ; Kollmeier M; Cox B; Fidaleo A; Sperling D; Pei X; Carver B; Coleman J; Lovelock M; Hunt M
    Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):125-9. PubMed ID: 22330997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreased acute toxicities of intensity-modulated radiation therapy for localized prostate cancer with prostate-based versus bone-based image guidance.
    Nakamura K; Mizowaki T; Inokuchi H; Ikeda I; Inoue T; Kamba T; Ogawa O; Hiraoka M
    Int J Clin Oncol; 2018 Feb; 23(1):158-164. PubMed ID: 28756594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-course, intensity-modulated radiotherapy for localized prostate cancer.
    Kupelian PA; Willoughby TR
    Cancer J; 2001; 7(5):421-6. PubMed ID: 11693901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute toxicity after image-guided intensity modulated radiation therapy compared to 3D conformal radiation therapy in prostate cancer patients.
    Wortel RC; Incrocci L; Pos FJ; Lebesque JV; Witte MG; van der Heide UA; van Herk M; Heemsbergen WD
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(4):737-44. PubMed ID: 25752386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Late Side Effects After Image Guided Intensity Modulated Radiation Therapy Compared to 3D-Conformal Radiation Therapy for Prostate Cancer: Results From 2 Prospective Cohorts.
    Wortel RC; Incrocci L; Pos FJ; van der Heide UA; Lebesque JV; Aluwini S; Witte MG; Heemsbergen WD
    Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):680-9. PubMed ID: 27055398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement in toxicity in high risk prostate cancer patients treated with image-guided intensity-modulated radiotherapy compared to 3D conformal radiotherapy without daily image guidance.
    Sveistrup J; af Rosenschöld PM; Deasy JO; Oh JH; Pommer T; Petersen PM; Engelholm SA
    Radiat Oncol; 2014 Feb; 9():44. PubMed ID: 24495815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of principal component analysis in predicting toxicity in prostate cancer patients treated with hypofractionated intensity-modulated radiation therapy.
    Vesprini D; Sia M; Lockwood G; Moseley D; Rosewall T; Bayley A; Bristow R; Chung P; Ménard C; Milosevic M; Warde P; Catton C
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e415-21. PubMed ID: 21477939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensity-modulated radiotherapy reduces toxicity with similar biochemical control compared with 3-dimensional conformal radiotherapy for prostate cancer: A randomized clinical trial.
    Viani GA; Viana BS; Martin JE; Rossi BT; Zuliani G; Stefano EJ
    Cancer; 2016 Jul; 122(13):2004-11. PubMed ID: 27028170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term Outcomes of a Dose-reduction Trial to Decrease Late Gastrointestinal Toxicity in Patients with Prostate Cancer Receiving Soft Tissue-matched Image-guided Intensity-modulated Radiotherapy.
    Sasaki N; Yamazaki H; Shimizu D; Suzuki G; Masui K; Nakamura S; Okabe H; Nishikawa T; Yoshida K
    Anticancer Res; 2018 Jan; 38(1):385-391. PubMed ID: 29277799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy.
    Vargas C; Martinez A; Kestin LL; Yan D; Grills I; Brabbins DS; Lockman DM; Liang J; Gustafson GS; Chen PY; Vicini FA; Wong JW
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1297-308. PubMed ID: 16029785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incremental changes verses a technological quantum leap: the additional value of intensity-modulated radiotherapy beyond image-guided radiotherapy for prostate irradiation.
    Ratnayake G; Martin J; Plank A; Wong W
    J Med Imaging Radiat Oncol; 2014 Aug; 58(4):503-10. PubMed ID: 25243269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of changing rectal dose volume parameters over time on late rectal and urinary toxicity after high-dose intensity-modulated radiotherapy for prostate cancer: A 10-years single centre experience.
    Fonteyne V; Sadeghi S; Ost P; Vanpachtenbeke F; Vuye P; Lumen N; De Meerleer G
    Acta Oncol; 2015 Jun; 54(6):854-61. PubMed ID: 25387271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is it time to tailor the prediction of radio-induced toxicity in prostate cancer patients? Building the first set of nomograms for late rectal syndrome.
    Valdagni R; Kattan MW; Rancati T; Yu C; Vavassori V; Fellin G; Cagna E; Gabriele P; Mauro FA; Baccolini M; Bianchi C; Menegotti L; Monti AF; Stasi M; Giganti MO; Fiorino C
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1957-66. PubMed ID: 21640511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypofractionated intensity-modulated radiotherapy (70 gy at 2.5 Gy per fraction) for localized prostate cancer: long-term outcomes.
    Kupelian PA; Thakkar VV; Khuntia D; Reddy CA; Klein EA; Mahadevan A
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1463-8. PubMed ID: 16169683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated intensity-modulated radiotherapy.
    Pervez N; Small C; MacKenzie M; Yee D; Parliament M; Ghosh S; Mihai A; Amanie J; Murtha A; Field C; Murray D; Fallone G; Pearcey R
    Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):57-64. PubMed ID: 19395192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of dose escalation with technological advances (intensity-modulated and image-guided radiotherapy) is not associated with increased morbidity for patients with prostate cancer.
    Pinkawa M; Piroth MD; Holy R; Djukic V; Klotz J; Krenkel B; Eble MJ
    Strahlenther Onkol; 2011 Aug; 187(8):479-84. PubMed ID: 21789739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Late Rectal Toxicity from Image-guided Intensity Modulated Radiotherapy for Prostate Cancer.
    Maki S; Itoh Y; Kubota S; Okada T; Nakahara R; Ito J; Kawamura M; Kamomae T; Naganawa S; Yoshino Y; Gotoh M; Ikeda M
    Anticancer Res; 2016 Jun; 36(6):2967-73. PubMed ID: 27272812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Local Protocol Variations for Image Guided Radiation Therapy in the Multicenter Dutch Hypofractionation (HYPRO) Trial: Impact of Rectal Balloon and MRI Delineation on Anorectal Dose and Gastrointestinal Toxicity Levels.
    Wortel RC; Heemsbergen WD; Smeenk RJ; Witte MG; Krol SDG; Pos FJ; Incrocci L
    Int J Radiat Oncol Biol Phys; 2017 Dec; 99(5):1243-1252. PubMed ID: 28943074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.